Subgroup multivariate analyses
| . | RR of NRM (95% confidence interval) . | P . | RR of death (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patients with hematologic malignancies receiving MA HCT (n = 103) | ||||
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 2.2 (0.3-16.7) | .44 | 3.1 (1.4-7.0) | < .01† |
| ≥ 3 | 10.2 (1.3-82.6) | .03† | 4.6 (1.9-11.0) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.2 (0.01-1.7) | .65 | 0.5 (0.2-1.0) | .06 |
| 11-20 | 0.9 (0.1-12.1) | .13 | 0.8 (0.3-1.8) | .56 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.3 (0.03-2.9) | .31 | 1.4 (0.5-3.7) | .53 |
| UMACH | 0.1 (0.01-4.9) | .25 | 0.9 (0.5-3.9) | .85 |
| TXCCC | 0.6 (0.1-5.8) | .65 | 1.1 (0.3-3.4) | .93 |
| All patients receiving MA HCT (n = 189) | ||||
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 1.9 (0.6-6.0) | .30 | 3.5 (1.1-11.0) | .04† |
| ≥ 3 | 5.5 (1.9-15.9) | < .01† | 5.3 (1.5-18.7) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.4 (0.1-1.0) | .04† | 0.4 (0.1-1.3) | .12 |
| 11-20 | 0.4 (0.1-1.3) | .13 | 0.9 (0.3-2.9) | .82 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.5 (0.2-1.6) | .25 | 2.0 (0.4-10.6) | .53 |
| UMACH | 0.5 (0.1-2.0) | .29 | 1.6 (0.2-11.8) | .85 |
| TXCCC | 0.9 (0.2-3.2) | .81 | 1.3 (0.2-8.3) | .82 |
| . | RR of NRM (95% confidence interval) . | P . | RR of death (95% confidence interval) . | P . |
|---|---|---|---|---|
| Patients with hematologic malignancies receiving MA HCT (n = 103) | ||||
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 2.2 (0.3-16.7) | .44 | 3.1 (1.4-7.0) | < .01† |
| ≥ 3 | 10.2 (1.3-82.6) | .03† | 4.6 (1.9-11.0) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.2 (0.01-1.7) | .65 | 0.5 (0.2-1.0) | .06 |
| 11-20 | 0.9 (0.1-12.1) | .13 | 0.8 (0.3-1.8) | .56 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.3 (0.03-2.9) | .31 | 1.4 (0.5-3.7) | .53 |
| UMACH | 0.1 (0.01-4.9) | .25 | 0.9 (0.5-3.9) | .85 |
| TXCCC | 0.6 (0.1-5.8) | .65 | 1.1 (0.3-3.4) | .93 |
| All patients receiving MA HCT (n = 189) | ||||
| HCT-CI | ||||
| 0* | 1.0 | 1.0 | ||
| 1-2 | 1.9 (0.6-6.0) | .30 | 3.5 (1.1-11.0) | .04† |
| ≥ 3 | 5.5 (1.9-15.9) | < .01† | 5.3 (1.5-18.7) | < .01† |
| Age, y | ||||
| 0-1* | 1.0 | 1.0 | ||
| 2-10 | 0.4 (0.1-1.0) | .04† | 0.4 (0.1-1.3) | .12 |
| 11-20 | 0.4 (0.1-1.3) | .13 | 0.9 (0.3-2.9) | .82 |
| Center | ||||
| CCHMC* | 1.0 | 1.0 | ||
| DFCI/CHB | 0.5 (0.2-1.6) | .25 | 2.0 (0.4-10.6) | .53 |
| UMACH | 0.5 (0.1-2.0) | .29 | 1.6 (0.2-11.8) | .85 |
| TXCCC | 0.9 (0.2-3.2) | .81 | 1.3 (0.2-8.3) | .82 |
CCHMC indicates Cincinnati Children's Hospital Medical Center; DFCI/CHB, Dana-Farber Cancer Institute/Children's Hospital Boston; UMACH, University of Minnesota Amplatz Children's Hospital; TXCCC, Texas Children's Cancer Center; RR, relative risk; NRM, nonrelapse mortality; NMA, nonmyeloablative; and MA, myeloablative.
Reference group.